Blood Cancer News and Research

RSS

Scientists use genetically engineered immune cells to fight Hodgkin and non-Hodgkin lymphoma cells

University of North Carolina Lineberger Comprehensive Cancer Center researchers reported promising early results from a clinical study of an investigational cellular immunotherapy that used a patient's own, genetically engineered immune cells to recognize and fight Hodgkin and non-Hodgkin lymphoma cells.

4 Dec 2018

UK scientists find new way to identify patients with aggressive lymphoma

UK scientists have found a new way to identify people with the most aggressive types of lymphoma who are less likely to respond to standard drugs.

3 Dec 2018

Study: 51% of patients alive two years after receiving CAR-T therapy for diffuse large B-cell lymphoma

A follow-up analysis of patients enrolled in a Phase I/II multi-center trial for diffuse large B-cell lymphoma reported 51 percent of patients receiving an anti-CD19 chimeric antigen receptor (CAR T) called axi-cel were still alive two years post-treatment.

3 Dec 2018

FDA approves new combination therapy for acute myeloid leukemia

Older patients with acute myeloid leukemia (AML) often aren't healthy enough to receive intensive chemotherapy, and gentler treatments aren't very effective in treating this aggressive blood cancer.

30 Nov 2018

Researchers identify inconspicuous protein as key to aggressive blood cancer

Five percent of acute leukemia cases are diagnosed as mixed lineage leukemia. MLL is an aggressive blood cancer that predominantly occurs in infants and has been difficult to treat.

29 Nov 2018

Abramson Cancer Center becomes the 28th member institution of National Comprehensive Cancer Network

The Abramson Cancer Center (ACC) at the University of Pennsylvania announced today that it is joining the National Comprehensive Cancer Network (NCCN) as its 28th member institution.

20 Nov 2018

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

Genentech, a member of the Roche Group , announced today that the randomized Phase III CLL14 study, which evaluated fixed-duration Venclexta® in combination with Gazyva® in people with previously untreated chronic lymphocytic leukemia and co-existing medical conditions, met its primary endpoint and showed a statistically significant reduction in the risk of disease worsening or death compared to standard-of-care Gazyva plus chlorambucil.

1 Nov 2018

Researchers uncover link between RNA abnormalities and multiple myeloma progression

Multiple myeloma is the second most common type of blood cancer where cancer cells accumulate in the bone marrow, crowding out healthy blood cells.

1 Nov 2018

Ten Allen Distinguished Investigators for 2018 announced by Paul G. Allen Frontiers Group

Nanoparticles that could reprogram a cancer patient's immune system inside their own body. Understanding a mysterious type of brain cell in the hopes of shedding new light on Alzheimer's disease. Reimagining nuclei, the DNA-storage compartments of our cells, as miniature lava lamps.

30 Oct 2018

Study suggests new strategy to kill melanoma cells

Think of the protein BH3 like a finger that turns off a cancer cell survival switch. The problem is that most cancer cells have found ways to remove this "finger" - commonly, by breaking the action of a gene called p53 that puts the BH3 finger in motion. Now think of Bcl-2 as the switch itself.

24 Oct 2018

Researchers develop promising targeted strategy to treat chemo-resistant blood cancer

Researchers from The Ottawa Hospital and the University of Ottawa have developed a promising targeted strategy to treat chemotherapy-resistant acute myeloid leukemia and a diagnostic test to determine which AML patients would most likely benefit from this treatment.

22 Oct 2018

Gene types that drive racial disparities in myeloma identified

Researchers at Mayo Clinic have identified three specific gene types that account for a known two-to-three-fold increase in myeloma diagnoses among African-Americans.

10 Oct 2018

'Supercharged' immune cells could help fight cancer

A type of 'supercharged' immune cell could be mass-produced to help fight cancer.

9 Oct 2018

Study sheds light on transport of enzyme involved in stem cell differentiation to DNA

Researchers at the Centre for Genomic Regulation in Barcelona, Spain, have identified the mechanism by which an important enzyme involved in the differentiation of stem cells is brought to the DNA.

3 Oct 2018

New analysis confirms value of minimal residual disease as prognostic indicator in multiple myeloma

Adaptive Biotechnologies today announced that Blood, the Journal of the American Society of Hematology, published online an analysis of patient samples from the Intergroupe Francophone du Myéloma 2009 trial.

1 Oct 2018

FDA permits marketing of ClonoSEQ assay to detect minimal residual disease in blood cancer patients

Today the U.S. Food and Drug Administration permitted marketing of ClonoSEQ assay, a next generation sequencing-based test for minimal residual disease in patients with acute lymphoblastic leukemiaor multiple myeloma. MRD is a measure of the amount of cancer cells remaining in a person's bone marrow.

30 Sep 2018

Verastem Oncology selects US Bioservices to dispense COPIKTRA capsules

US Bioservices, a specialty pharmacy that is a part of AmerisourceBergen, today announced that it has been selected by Verastem OncologyTM to dispense COPIKTRA (duvelisib) capsules.

28 Sep 2018

Research shows possibility to postpone cumbersome treatment for low-risk MDS patients

It's possible to postpone the introduction of blood transfusions for an average of 17 months for patients with the low-risk variant of MDS blood cancer, provided they are given erythropoiesis-stimulating agents, which stimulate the body to produce red blood cells, according to a dissertation at Sahlgrenska Academy, Sweden.

24 Sep 2018

$CHMP grants positive opinion for VENCLYXTO plus rituximab for treating relapsed/refractory CLL$

CHMP grants positive opinion for VENCLYXTO plus rituximab for treating relapsed/refractory CLL

AbbVie, a research-based global biopharmaceutical company, announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has granted a positive opinion for VENCLYXTO® in combination with rituximab for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia who have received at least one prior therapy.

21 Sep 2018

Progenitor cells for human bone and cartilage have been identified

Research published today describes for the first time the identification of human skeletal stem cells. The discovery may enable the development of novel therapeutic strategies for diseases that cause skeletal degeneration.

20 Sep 2018